Ross D, Whitehead M
Menopause Clinic, King's College Hospital, London, UK.
Curr Opin Obstet Gynecol. 1995 Feb;7(1):63-8.
Tamoxifen has a well established place in the adjuvant therapy of primary carcinoma of the breast. Its effects on breast cancer cells are both anti-oestrogenic and non-oestrogen-receptor mediated. Tamoxifen has oestrogenic effects on non-breast tissues such as liver, bone, the cardiovascular system and the urogenital tract. The effect on the endometrium is to increase the incidence of polyps, hyperplasia and carcinoma. Again, non-oestrogen receptor-mediated actions may be involved. With more widespread use of tamoxifen now being advocated, for instance in the primary prevention of breast cancer, careful assessment of benefit and risk is required.
他莫昔芬在乳腺癌的辅助治疗中具有既定地位。它对乳腺癌细胞的作用既有抗雌激素作用，也有非雌激素受体介导的作用。他莫昔芬对肝脏、骨骼、心血管系统和泌尿生殖道等非乳腺组织具有雌激素样作用。对子宫内膜的影响是增加息肉、增生和癌的发生率。同样，可能涉及非雌激素受体介导的作用。鉴于现在主张更广泛地使用他莫昔芬，例如用于乳腺癌的一级预防，需要仔细评估其益处和风险。
